Coinfection of Hepatitis B and C Viruses and Risk of Hepatocellular Carcinoma: Systematic Review and Meta-analysis.

Abdullah A Awadh, Abdulrahman A Alharthi, Basil A Alghamdi, Seraj T Alghamdi, Mohammed K Baqays, Ibrahim S Binrabaa, Israa A Malli
Author Information
  1. Abdullah A Awadh: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  2. Abdulrahman A Alharthi: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  3. Basil A Alghamdi: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  4. Seraj T Alghamdi: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  5. Mohammed K Baqays: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  6. Ibrahim S Binrabaa: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  7. Israa A Malli: Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.

Abstract

Introduction: hepatitis B and C are viral infections causing chronic liver inflammation and, when left untreated, lead to cirrhosis and a risk for hepatocellular carcinoma, the most common type of primary liver cancer with high mortality. The hepatitis B virus-hepatitis C virus (HBV-HCV) Coinfection leads to a faster progression to advanced liver diseases and higher hepatocellular carcinoma (HCC) risk than monoinfection. Unlike the relative risk for HCC due to either HBV or HCV, no recent analysis of the risk for HBV-HCV Coinfection exists.
Methods: Based on PRISMA recommendations and guidelines, we developed a search strategy by combining the keywords ("hepatitis B") and ("hepatitis C") and ("hepatocellular carcinoma" or "liver cancer"). First, we performed a title and abstract screening and, later, a full-text screening. We extracted the demographic characteristics, such as gender, age, study design, sample size, country, and biomarkers of hepatitis B surface antigen (HBsAg), HBV DNA, HBeAg, anti-HCV, and HCV RNA. The data were assessed for quality, and the Review Manager software was used for the meta-analysis.
Results: We included 63 studies. The pooled analysis showed that the risk of HCC was significantly higher in the case-cohort who were positive for HBsAg (odds ratio [OR] = 9.70 [3.75, 25.12], = 0.0001), HBV DNA or HBeAg (OR = 22.77 [10.00, 51.88], = 0.0001), HBV and HCV Coinfection (OR = 46.07 [26.33, 80.60], = 0.0001) than the control cohort.
Conclusion: Chronic HBV and HCV infections are major risk factors for HCC, and their Coinfection was significantly associated with an increased risk of HCC than monoinfection.

Keywords

References

  1. J Viral Hepat. 2019 Jul;26(7):866-872 [PMID: 30924226]
  2. Orv Hetil. 2009 Jan 4;150(1):19-26 [PMID: 19091671]
  3. J Infect Dis. 1992 May;165(5):831-4 [PMID: 1314869]
  4. Cancer Res. 2014 Jun 1;74(11):2913-21 [PMID: 24840647]
  5. BMJ Open. 2019 Jun 28;9(6):e026409 [PMID: 31256022]
  6. Int J Cancer. 2013 Jul 15;133(2):437-45 [PMID: 23233429]
  7. J Gastrointest Cancer. 2011 Dec;42(4):228-35 [PMID: 20809396]
  8. Hepatology. 2018 Nov;68(5):1817-1832 [PMID: 29790588]
  9. JAMA Oncol. 2017 Dec 1;3(12):1683-1691 [PMID: 28983565]
  10. Hepatology. 2014 Dec;60(6):1871-8 [PMID: 25065513]
  11. J Cell Physiol. 2019 Aug;234(8):12188-12225 [PMID: 30536673]
  12. Clin Biochem. 2011 Oct;44(14-15):1235-40 [PMID: 21854762]
  13. World J Surg. 2011 May;35(5):1063-71 [PMID: 21380583]
  14. Viral Immunol. 2016 Dec;29(10):536-545 [PMID: 27676210]
  15. PLoS One. 2014 Nov 05;9(11):e112184 [PMID: 25372403]
  16. Tumour Biol. 2014 Aug;35(8):7307-15 [PMID: 24833096]
  17. Int J Circumpolar Health. 2013 May 13;72:20282 [PMID: 23687637]
  18. Hepatobiliary Pancreat Dis Int. 2014 Apr;13(2):162-72 [PMID: 24686543]
  19. Int J Lab Hematol. 2016 Feb;38(1):42-9 [PMID: 26362346]
  20. Biomedicines. 2020 Jun 25;8(6): [PMID: 32630610]
  21. Mol Med Rep. 2017 Sep;16(3):2411-2416 [PMID: 28656273]
  22. Hepatology. 2018 Aug;68(2):723-750 [PMID: 29624699]
  23. BMC Med Genomics. 2019 Oct 28;12(1):147 [PMID: 31660973]
  24. Clin Liver Dis. 2011 May;15(2):261-79, vii-x [PMID: 21689612]
  25. Ann Oncol. 2009 Oct;20(10):1736-40 [PMID: 19549710]
  26. J Hepatol. 2013 Feb;58(2):287-96 [PMID: 23099188]
  27. HPB (Oxford). 2013 Dec;15(12):985-90 [PMID: 23607636]
  28. Eur J Intern Med. 2010 Apr;21(2):127-30 [PMID: 20206885]
  29. Mayo Clin Proc. 2012 Jan;87(1):17-24 [PMID: 22212964]
  30. Lancet Oncol. 2009 Nov;10(11):1111-8 [PMID: 19880065]
  31. Epidemiology. 2016 Jan;27(1):14-20 [PMID: 26443934]
  32. Int J Cancer. 2020 Nov 15;147(10):2743-2753 [PMID: 32406072]
  33. J Gastroenterol Hepatol. 2016 Jul;31(7):1291-9 [PMID: 26729319]
  34. Open Med. 2009;3(3):e123-30 [PMID: 21603045]
  35. Innate Immun. 2012 Oct;18(5):700-8 [PMID: 22330637]
  36. Anticancer Agents Med Chem. 2011 Jul;11(6):493-9 [PMID: 21554201]
  37. Pathol Biol (Paris). 2010 Apr;58(2):152-5 [PMID: 19875248]
  38. Scand J Gastroenterol. 2010 Aug;45(7-8):944-52 [PMID: 20384529]
  39. Int J Cancer. 2011 Jan 1;128(1):176-84 [PMID: 20232388]
  40. J Hepatol. 2013 Oct;59(4):696-700 [PMID: 23751755]
  41. Dig Liver Dis. 2010 Jul;42 Suppl 3:S215-22 [PMID: 20547306]
  42. J Clin Oncol. 2011 Sep 20;29(27):3643-50 [PMID: 21859997]
  43. Nat Rev Gastroenterol Hepatol. 2016 Oct;13(10):561-2 [PMID: 27580683]
  44. Liver Int. 2015 Sep;35(9):2155-66 [PMID: 25752327]
  45. Arch Virol. 2020 Jan;165(1):33-42 [PMID: 31630275]
  46. J Gastroenterol Hepatol. 2011 Aug;26(8):1333-7 [PMID: 21443669]
  47. J Viral Hepat. 2017 Nov;24(11):990-997 [PMID: 28499070]
  48. Medicine (Baltimore). 2019 Sep;98(38):e17275 [PMID: 31568008]
  49. J Formos Med Assoc. 2020 Jan;119(1 Pt 1):3-11 [PMID: 31627984]
  50. Gastroenterology. 2019 Nov;157(5):1264-1278.e4 [PMID: 31356807]
  51. Br J Biomed Sci. 2019 Jan;76(1):35-41 [PMID: 30421643]
  52. Clin Microbiol Infect. 2015 Nov;21(11):969-74 [PMID: 26163104]
  53. Gut. 2014 Mar;63(3):506-14 [PMID: 23676440]
  54. Liver Int. 2003 Dec;23(6):405-9 [PMID: 14986813]
  55. J Clin Microbiol. 1998 Jul;36(7):2084-6 [PMID: 9650968]
  56. World J Hepatol. 2011 Jan 27;3(1):24-30 [PMID: 21307984]
  57. J Gastroenterol. 2019 May;54(5):427-436 [PMID: 30506232]
  58. Indian J Gastroenterol. 2014 Jan;33(1):12-8 [PMID: 24006121]
  59. J Clin Lab Anal. 2020 Feb;34(2):e23075 [PMID: 31659795]
  60. Aliment Pharmacol Ther. 2020 Sep;52(5):866-876 [PMID: 32697871]
  61. J Viral Hepat. 2011 Jul;18(7):e232-41 [PMID: 21692938]
  62. Hepatology. 2015 Sep;62(3):737-50 [PMID: 25678021]
  63. Kaohsiung J Med Sci. 2013 Aug;29(8):451-9 [PMID: 23906236]
  64. Cardiovasc Intervent Radiol. 2015 Aug;38(4):957-63 [PMID: 25413262]
  65. Hepatology. 2011 Apr;53(4):1237-45 [PMID: 21480328]
  66. J Gastroenterol Hepatol. 2011 Dec;26(12):1757-64 [PMID: 21615789]
  67. Gastroenterology. 2012 Jun;142(7):1468-75 [PMID: 22342990]
  68. J Neurochem. 2019 Jan;148(2):188-203 [PMID: 30347482]
  69. Medicine (Baltimore). 2016 Apr;95(15):e3284 [PMID: 27082566]
  70. BMC Cancer. 2012 Oct 05;12:452 [PMID: 23039099]
  71. J Natl Cancer Inst. 2011 Nov 16;103(22):1686-95 [PMID: 22021666]
  72. J Gastrointest Surg. 2017 Mar;21(3):487-495 [PMID: 28050767]
  73. Cancer Res. 1991 May 15;51(10):2531-5 [PMID: 1902393]
  74. J Formos Med Assoc. 2021 Jan;120(1 Pt 3):621-628 [PMID: 32718890]
  75. Hepatology. 2013 Jun;57(6):2135-42 [PMID: 23322699]
  76. Clin Mol Hepatol. 2021 Jul;27(3):512-514 [PMID: 34153973]
  77. J Hepatol. 2017 Nov;67(5):909-917 [PMID: 28684103]
  78. mBio. 2015 Dec 08;6(6):e01500-15 [PMID: 26646011]
  79. Aliment Pharmacol Ther. 2020 Jan;51(2):216-230 [PMID: 31746482]
  80. Int J Cancer. 2020 Jul 15;147(2):317-330 [PMID: 31597196]
  81. Oncol Rep. 2010 Mar;23(3):861-7 [PMID: 20127030]

Word Cloud

Created with Highcharts 10.0.0risk=BHCCHBVCliverhepatitiscoinfectionHCVHepatitishepatocellularcarcinoma00001infectionsHBV-HCVhighermonoinfectionanalysis"hepatitisscreeningHBsAgDNAHBeAgReviewmeta-analysissignificantlyORIntroduction:viralcausingchronicinflammationleftuntreatedleadcirrhosiscommontypeprimarycancerhighmortalityvirus-hepatitisvirusleadsfasterprogressionadvanceddiseasesUnlikerelativedueeitherrecentexistsMethods:BasedPRISMArecommendationsguidelinesdevelopedsearchstrategycombiningkeywordsB"C""hepatocellularcarcinoma""livercancer"Firstperformedtitleabstractlaterfull-textextracteddemographiccharacteristicsgenderagestudydesignsamplesizecountrybiomarkerssurfaceantigenanti-HCVRNAdataassessedqualityManagersoftwareusedResults:included63studiespooledshowedcase-cohortpositiveoddsratio[OR]970[3752512]2277[10005188]4607[26338060]controlcohortConclusion:ChronicmajorfactorsassociatedincreasedCoinfectionVirusesRiskHepatocellularCarcinoma:SystematicMeta-analysis

Similar Articles

Cited By

No available data.